Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the Bioavailability of Pramlintide
This study has been completed.
Study NCT00042471   Information provided by Amylin Pharmaceuticals, Inc.
First Received: July 30, 2002   Last Updated: November 5, 2007   History of Changes

July 30, 2002
November 5, 2007
June 2002
 
 
 
Complete list of historical versions of study NCT00042471 on ClinicalTrials.gov Archive Site
 
 
 
Evaluation of the Bioavailability of Pramlintide
 

This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin.

 
Phase II
Interventional
Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Bio-availability Study
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
Drug: Pramlintide acetate
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
 
 
 

Inclusion Criteria:

  • HbA1c value between 6-12%
  • BMI <= 27 kg/m2 or BMI >=30 to <= 45 kg/m2
  • Consistent insulin regimen for 2 months prior to screening
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00042471
 
137-153
Amylin Pharmaceuticals, Inc.
 
 
Amylin Pharmaceuticals, Inc.
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP